108 results on '"Julian Schulze"'
Search Results
2. SAT-376 Hepatitis C virus specific CD8+ T cells of patients with acute and chronic HCV infection display high expression of CD96 and other co-inhibitory molecules
3. LBP-029 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
4. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
5. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B
6. Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study
7. Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos (t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial
8. Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients
9. Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
10. Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response
11. Efficacy and safety of vaccination againts SARS-CoV-2 in patients with vascular liver disease
12. Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
13. Classification of HCV-specific CD8+ T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage
14. T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network
15. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
16. Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)
17. Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)
18. Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure
19. Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study
20. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
21. TOP-369 HEV replication and genomic diversification in the human kidney
22. Mechanisms of CD8+ T-cell failure in chronic hepatitis E virus infection
23. Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study
24. Classification of HCV-specific CD8+ T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage
25. Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure
26. Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)
27. T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network
28. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
29. TOP-110 - Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos (t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial
30. SAT-156 - Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response
31. FRI-248 - Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study
32. FRI-244 - Identification of resistance-associated variants after sofosbuvir treatment in chronic hepatitis E patients
33. THU-290 - Efficacy and safety of vaccination againts SARS-CoV-2 in patients with vascular liver disease
34. OS-068 - Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
35. Hepatitis D coinfection is associated with enhanced CXCR3 receptor expression of CD4 memory T cells and intrahepatic CXCR3 ligand expression compared to chronic hepatitis B patients
36. Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial
37. Deviations of the peripheral blood and intrahepatic immune cell landscape between NAFLD patients and healthy controls
38. Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals
39. Hepatitis C virus chronicity is associated with a tox-1(high), Eomes(high), T-bet(dim) and PD1(high) phenotype of HCV-specific CD8+ T cells
40. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study
41. Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial
42. SAT341 - Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience
43. FRI391 - Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure
44. FRI385 - Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study)
45. THU197 - Classification of HCV-specific CD8+ T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage
46. OS069 - Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study
47. OS072A - T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network
48. OS003 - Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)
49. GS006 - Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
50. Deviations of the peripheral blood and intrahepatic immune cell landscape between NAFLD patients and healthy controls
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.